Krsnaa Diagnostics Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹159Cr
- −3.6% YoY
- −13.1% QoQ
- Net profit
- ₹16Cr
- −27.3% YoY
- −30.4% QoQ
- Margin
- 30%
- +1 pp YoY
- −2 pp QoQ
The short version
Krsnaa Diagnostics is focusing on organic growth and expects year-on-year expansion in volumes and revenues. Krsnaa Diagnostics expects growth to return in subsequent quarters after interim setbacks (Page 17).
From Krsnaa Diagnost.'s Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Krsnaa Diagnostics is focusing on organic growth and expects year-on-year expansion in volumes and revenues.
- Retail segment showing strong momentum, with retail revenue growing nearly 8x YoY in Q3 FY '26, contributing 8% of total revenue; network expanded to over 3,000 touch points.
- Expectation of 15-25% growth in retail touch points in coming quarters as part of strategic, long-term network building.
- Rajasthan PPP project anticipated to contribute approximately INR 200 crores in revenue in FY '27, with full potential revenue expected by end of FY '27 rather than spilling into FY '28.
- Core base business (ex-B2C and ex-Rajasthan) targeted to grow in the higher teens percentage-wise annually.
- Both pathology and radiology segments in base business expected to grow in tandem, with potential slightly better growth in radiology next year due to new projects.
2 more points from Krsnaa Diagnost.'s call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Krsnaa Diagnost. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Maharashtra MRI project: Ongoing capex incurred, but revenue delayed due to site and compliance clearance delays; 10 MRI sites nearing inauguration expected in Q4 FY26.
- Rajasthan project: Around 20 labs installed, 300 collection centers in progress; majority expected by Q4 FY26 with some spillover into Q1 FY27; involves capital investment with front-loaded expenses.
- Selective tender participation: Management is cautious and selective about new PPP tenders, focusing on projects with clearances and feasibility to ensure capital discipline.
2 more points from Krsnaa Diagnost.'s call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what Krsnaa Diagnost. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Krsnaa Diagnostics is selective about the PPP projects it undertakes, focusing on tenders that can be successfully delivered.
- The largest rollout currently underway is the Rajasthan project.
- Apart from Rajasthan and Maharashtra radiology tender under implementation, there are a couple of other projects in the pipeline.
- No major new order wins have occurred in the past 12 months except Rajasthan tender.
2 more points from Krsnaa Diagnost.'s call on order book
Create a free account to keep reading this call
Krsnaa Diagnost. — Quarterly revenue & net profit
Krsnaa Diagnost. Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 159 | 165 | -3.6% | 183 | -13.1% |
| Operating profit (EBITDA) | 48 | 48 | 0% | 58 | -17.2% |
| Operating margin | 30% | 29% | +1 pp | 32% | -2 pp |
| Profit before tax | 21 | 28 | -25% | 31 | -32.3% |
| Net profit (PAT) | 16 | 22 | -27.3% | 23 | -30.4% |
| EPS (₹) | 5.08 | 6.69 | -24.1% | 7.16 | -29.1% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹240 Cr, net profit ₹25 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Krsnaa Diagnostics's management said in earlier quarters
Others in Healthcare Services this season
- Vijaya Diagnostic Centre (Q3 FY26)
FY '27 capex of INR 100-120 crores planned, supporting network expansion (Page 5). Key concall takeaways from Vijaya Diagnostic Centre's Q3 FY26 earnings call —
- Aster DM Quality (Q3 FY26)
Mature hospitals show steady revenue growth of 14%, hospitals 3-7 years old growing at 10%, and new assets under 3 years growing at 19%. Key concall takeaways…
- Chandan Healthca (Q3 FY26)
The company plans to open 100 new labs within three years, with an overall capex of INR100 crores for this expansion. Key concall takeaways from Chandan…
- Rainbow Childrens Medicare (Q3 FY26)
Revenue growth for the quarter was 12% YoY; 9% for the first 9 months of the financial year. Key concall takeaways from Rainbow Childrens Medicare Ltd's Q3…
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Krsnaa Diagnost. and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Krsnaa Diagnost. Q3 FY26 results?
Krsnaa Diagnostics is focusing on organic growth and expects year-on-year expansion in volumes and revenues. Krsnaa Diagnostics expects growth to return in subsequent quarters after interim setbacks (Page 17).
What is Krsnaa Diagnost. share price analysis?
Krsnaa Diagnost. currently shows a neutral. The stock trades at a P/E of 19.1 with a market cap of ₹1,866 Cr. Investors should review the full earnings analysis for detailed insights.
Is Krsnaa Diagnost. planning capital expenditure?
Maharashtra MRI project: Ongoing capex incurred, but revenue delayed due to site and compliance clearance delays; 10 MRI sites nearing inauguration expected in Q4 FY26.
Keep Krsnaa Diagnost. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
